Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 23617461)

  • 1. Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.
    Scartozzi M; Giampieri R; Loretelli C; Mandolesi A; del Prete M; Biagetti S; Alfonsi S; Faloppi L; Bianconi M; Bittoni A; Bearzi I; Cascinu S
    Future Oncol; 2013 Aug; 9(8):1207-14. PubMed ID: 23617461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
    Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
    Woo J; Palmisiano N; Tester W; Leighton JC
    Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
    Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
    J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
    Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
    Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16 infection of HaCaTs is dependent on β4 integrin, and α6 integrin processing.
    Aksoy P; Abban CY; Kiyashka E; Qiang W; Meneses PI
    Virology; 2014 Jan; 449():45-52. PubMed ID: 24418536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone-related protein regulates integrin α6 and β4 levels via transcriptional and post-translational pathways.
    Bhatia V; Mula RV; Falzon M
    Exp Cell Res; 2013 Jun; 319(10):1419-30. PubMed ID: 23499737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer.
    Galal KM; Khaled Z; Mourad AM
    Indian J Cancer; 2011; 48(1):47-54. PubMed ID: 21248446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
    Dempke WC; Heinemann V
    Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
    Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
    Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
    Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
    J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time imaging of integrin β4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing.
    Elaimy AL; Wang M; Sheel A; Brown CW; Walker MR; Amante JJ; Xue W; Chan A; Baer CE; Goel HL; Mercurio AM
    J Cell Sci; 2019 Jul; 132(15):. PubMed ID: 31262785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UNC5C‑knockdown enhances the growth and metastasis of breast cancer cells by potentiating the integrin α6/β4 signaling pathway.
    Yuan M; Xie F; Xia X; Zhong K; Lian L; Zhang S; Yuan L; Ye J
    Int J Oncol; 2020 Jan; 56(1):139-150. PubMed ID: 31789389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α6β4 Integrin Genetic Variations (A380T and R1281W) and Breast Cancer Risk in an Argentinian Population.
    Acosta KB; Lorenzini Campos MN; Etcheverry SB; Zapata PD
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.